Strategic alliances and alliance management professional development opportunities are aplenty this spring, including online and in-person options. You can find us speaking on the following venues:

March 29, 2022 - ASAP Webinar: Leaning into the Future: Priorities for Biopharma Alliance Professionals
​
April 20 - 21, 2022 - ASAP Global Alliance Summit: Master Class Helping Your Partners Help You: Using the Power of Positive Influence and panel discussion How Alliance Professionals Deliver Value in BioPharma Commercial Alliances

May 9 - 11, 2022: Strategic Alliance Management Congress: Top Five Opportunities for Getting a Little Better Every Day

May 18 - 19, 2022 - Biopharma Project Managers' Conference: Everyone Needs Some Alliance Management Skills in the Biopharma Ecosystem

Click more for details about these presentations and links to the...

This is Part Four of a Four Part post on adapting and applying certain principles of agile management as a means of meeting the increased demand for alliance management services as the scale, scope, and complexity of biopharmaceutical asset, service, digital, and data alliances and partnerships grows.

Download a pdf of all four parts of “Reimagining Alliance Management as an Agile Capability” plus “What to Do When it Gets ‘Just Too Hard.’”  

Read Part One, Part Two, or Part Three of "Reimagining Alliance Management as an Agile Capability" Practice Component 3:  Adapting the Alliance Management Organization

Typically, the resourcing model has been that each alliance has one alliance manager and that each individual has responsibility for multiple alliances. Certainly, there are exceptions for very large and complex alliances, and in advanced companies that have recognized the need for new ways of working, but by and large the traditional model remains entrenched. This means that alliance management functions, groups, or teams do not operate as teams; they operate as collections of individual contributors. Agility depends on purpose driv...

In 2016, former US President Jimmy Carter announced that he no longer required treatment for his metastatic melanoma that had spread to his brain and liver. After six months of being treated with the immunotherapy pembrolizumab (trade name KEYTRUDA), together with surgery and radiation therapy, doctors had seen no sign of his disease for three months. This was a remarkable development—before pembrolizumab was approved in 2011, President Carter’s cancer likely would have been fatal.

Known as a “checkpoint inhibitor” pembrolizumab and other drugs in its class work—in simplest terms—by turbocharging the body’s immune system so that it can fight cancer. Its success, and the success of other similar drugs, such as avelumab (trade name BAVENCIO), and nivolumab (trade name OPDIVO), have unleashed a tsunami of clinical collaborations to identify how using these drugs in combination might expand and extend their significant patient benefits—and maximize their value to the biopharma companies that are de...

Jan Twombly, president of The Rhythm of Business is joined by Judy Baselice, director, alliance management at Pfizer and Ellen Locker, executive director, alliance management Merck & Co. at the 2018 ASAP Biopharma Conference in an interactive discussion about the complex web of agreements, restrictions, and obligations resulting from the explosion of clinical collaborations to create combination therapies....